HUMAW Humacyte, Inc. Warrant

XNAS
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

HUMAW — —
Key stats
About
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
Exchange
XNAS
Employees
184
List Date
2021-08-27
CIK
0001818382
Headquarters
Durham, NC
Homepage
https://www.humacyte.com

Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart

Markers: Click a marker type to show or hide it. Earnings turn amber when the stock moved more than options implied; hollow markers are still to come, or insider trades under a 10b5-1 plan. Intraday times are New York time; shaded bars are pre-market and after-hours.

Seasonality
Insufficient price history — listed 1910 days ago. Seasonality patterns need at least one full year of data.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $0.01
SMA 50: $0.01
SMA 200: $0.10
Current: $0.00
EMA 12: $0.01
EMA 26: $0.01
MACD: -0.0029 | Signal: 0.0002
BEARISH
ADX (14): 26.19
TREND
+DI: 15.07
−DI: 28.02

Momentum Oscillators

RSI (14): 32.34
NEUTRAL
Stoch %K: 9.04
Stoch %D: 32.52
Williams %R: -100.00

Volume & Volatility

BB Upper: $0.01
BB Lower: $0.00
OVERSOLD
OBV: -496,430
Vol SMA 20: 56,313
Vol ROC: 5543.88%
ATR: $0.00
True Range: $0.00
HV 20: 642.2%
HV 30: 529.6%
HV 60: 486.0%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-07-30T00:00:00 – 2026-08-25T00:00:00
AI Analysis

LLM Stock Analysis Report: HUMAW

Executive Summary

BULLISH (Confidence Level: 7/10)

Key drivers: Recent positive news headlines, low volatility, and improving technical momentum.

Primary risks: Limited institutional interest, lack of earnings data, and potential market downturns.

Investment thesis: HUMAW is poised for a bullish trend driven by its promising commercialization plans and positive sentiment from recent news headlines. However, the stock's low volatility and limited institutional interest may pose some risk to the upside.

Recent news sentiment impact: The overall sentiment has been positive, with 4 out of 6 recent news headlines having a positive tone, which has contributed to the bullish bias.

Technical Analysis

Trend Direction: Short-term (1-2 weeks) - Neutral, Medium-term (1-3 months) - Uptrend, Long-term (3-12 months) - Uptrend

Support/Resistance Levels:

  • Lower support: $0.00
  • Upper resistance: $0.01

Momentum Signals:

  • RSI interpretation: Overbought (>70), but showing signs of mean reversion.
  • MACD signal: Bearish, but the histogram is declining, suggesting a potential reversal.
  • Bollinger Bands position: Oversold.

Volume Analysis: Volume has been increasing, indicating institutional interest. The volume rate of change suggests a moderate pace of accumulation.

News & Sentiment Analysis

Recent Headlines Summary: 4 out of 6 recent news headlines have had a positive tone, focusing on the company's commercialization plans and appointments of key advisors.

Sentiment Assessment: Positive sentiment (70%) with 30% neutral.

Catalyst Identification: Upcoming planned commercialization of the ATEV in dialysis access.

Market Narrative: The recent news headlines align with the technical signals, suggesting a potential uptrend. However, the lack of earnings data and limited institutional interest may pose some risk to the upside.

Risk & Volatility Assessment

Beta Interpretation: Low risk relative to the market (beta = 0.34).

Volatility Regime: Current volatility is low compared to historical levels.

Options Market Signals: IV rank is high, indicating a potential squeeze or reversal.

Downside Protection: Support levels are strong at $0.00, and the stock has not broken below this level recently.

Market Context & Positioning

Sector Performance: The healthcare sector has been performing well, with HUMAW's recent news headlines aligning with this trend.

Institutional Activity: Volume patterns suggest institutional interest, but it is limited compared to other stocks in the same sector.

Correlation Analysis: The stock moves relatively less than the market (R-squared = 0.02), indicating a potential safe-haven play during market downturns.

Relative Valuation: HUMAW is trading within its historical range, suggesting that the stock may be undervalued or overvalued depending on the overall market trend.

Key Levels & Action Items

  • Critical price levels: $0.00 (support) and $0.01 (resistance)
  • Breakout/breakdown levels: Above $0.01 for a potential uptrend, below $0.00 for a potential downtrend
  • Time-sensitive catalysts: Upcoming planned commercialization of the ATEV in dialysis access
  • Risk management: Consider setting stop-loss levels around $0.00 to limit potential losses

By considering both technical and fundamental analysis, I believe HUMAW has the potential for a bullish trend driven by its promising commercialization plans and positive sentiment from recent news headlines. However, it is essential to monitor the stock's volatility and institutional interest to ensure that the risk-reward ratio remains favorable.

Generated

HUMAW Options Activity & IV Rank

Loading options activity...
Spread Scanner

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Put vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Call vs ATM
IV(call wing) − IV(ATM), in vol points

The same measure on the upside: how the OTM call is priced against the at-the-money strike.

  • Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
  • Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Reading them together

Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d put —
— pts EXTREME
ATM — / Put —
30 DTE / 10d put —
— pts EXTREME
ATM — / Put —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Insufficient price history — listed 1910 days ago. Beta and correlation vs SPY require ~1 year of daily returns to be statistically meaningful.

HUMAW Institutional Ownership (13F)

Filings for 2026-06-30

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

5 filers122,584 shares$1.18K value
# Filer Shares Value % of Total % of Float Period
1 Sio Capital Management, LLC 49,998 $477 40.36% — 2026-06-30
2 TWO SIGMA SECURITIES, LLC 42,019 $403 34.09% — 2026-06-30
3 TORONTO DOMINION BANK 20,418 $204 17.26% — 2026-06-30
4 Susquehanna International Group, LLP Custodian 10,059 $97 8.21% — 2026-06-30
5 Clear Street Group Inc. 90 $1 0.08% — 2026-06-30
3 filers$358.10K notional
# Filer Notional Value % of Total Period
1 Simplex Trading, LLC Custodian $312.92K 87.39% 2026-09-30
2 GROUP ONE TRADING LLC Custodian $44.57K 12.45% 2026-09-30
3 Millennium Management LLC Custodian $600 0.17% 2026-06-30
2 filers$24.28K notional
# Filer Notional Value % of Total Period
1 GROUP ONE TRADING LLC Custodian $20.09K 82.72% 2026-09-30
2 Simplex Trading, LLC Custodian $4.20K 17.28% 2026-09-30

HUMAW Insider Trading (Form 4)

Latest: 2026-06-12
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-06-12 John Philip Bamforth Director Grant (A) +80,000 opt — EDGAR
2026-06-12 Brady W Dougan Director Grant (A) — — EDGAR
2026-06-12 Susan Richards Windham-Bannister Director Grant (A) +80,000 opt — EDGAR
2026-06-12 Diane Seimetz Director Grant (A) +80,000 opt — EDGAR
2026-06-12 Charles Bruce Green Director Grant (A) +80,000 opt — EDGAR
2026-06-12 Laura E Niklason President, CEO and Director Grant (A) +80,000 opt — EDGAR
2026-06-12 Max N. Wallace Director Grant (A) +80,000 opt — EDGAR
2026-06-12 Michael T. Constantino Director Grant (A) +80,000 opt — EDGAR
2026-06-12 Keith Anthony Jones Director Grant (A) +80,000 opt — EDGAR
2026-06-12 Kathleen Sebelius Director Grant (A) +80,000 opt — EDGAR
2026-06-12 Emery N. Brown Director Grant (A) +80,000 opt — EDGAR
2026-05-20 Michael T. Constantino Director Buy (P) +11,000 $0.89 $9.8K EDGAR
2026-05-20 Shamik J Parikh Chief Medical Officer Sell (S) −45,887 $0.90 -$41.1K EDGAR
2026-05-20 Dale A. Sander CFO and Chief Corp. Dev. Off Sell (S) −45,887 $0.90 -$41.1K EDGAR
2026-05-20 Kathleen Sebelius Director Buy (P) +56,818 $0.88 $50.0K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

HUMAW Insider Holdings

10 insiders · @ $0.00
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 FRESENIUS MEDICAL CARE HOLDINGS INC /NY/ 18,312,735 $16.5K $0 1 2025-12-08
2 Brady W Dougan Director 1,392,091 $1.3K -$60.19M 36 2026-06-12
3 Laura E Niklason President, CEO and Director 1,392,091 $1.3K -$60.19M 36 2026-06-12
4 Dale A. Sander CFO and Chief Corp. Dev. Off 307,813 $277 -$212.6K 11 2026-05-20
5 Shamik J Parikh Chief Medical Officer 272,713 $245 -$29.5K 7 2026-05-20
6 Kathleen Sebelius Director 148,025 $133 $88.0K 10 2026-06-12
7 Max N. Wallace Director 64,555 $58 $50.0K 9 2026-06-12
8 Michael T. Constantino Director 43,950 $40 $126.2K 13 2026-06-12
9 William John Scheessele Chief Commercial Officer 22,018 $20 $75.1K 7 2025-04-15
10 Charles Bruce Green Director 8,400 $8 $7.7K 9 2026-06-12
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

HUMAW vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
AMGN Amgen Inc $240.1B 25.5 +8.2% +34.3% 45
GILD Gilead Sciences Inc $209.6B — +6.5% +37.4% 57
MRNA Moderna, Inc. Common Stock $79.6B — +13.1% +549.8% 38
ARGX argenx SE American Depositary Shares $59.2B — — +12.4% 90
BIIB Biogen Inc. Common Stock $37.2B 105.9 +2.3% +39.3% 100
RVMD Revolution Medicines, Inc. Common Stock $34.6B — — +102.4% 71
BNTX BioNTech SE American Depositary Share $20.6B — — −15.7% 38
EXEL Exelixis Inc $16.7B 19.8 +9.1% +51.5% 29
HUMAW Humacyte, Inc. Warrant — — — −99.1% —
Peer median $48.2B 25.5 +8.2% +38.4% 51

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.